According to Enzo Biochem's latest financial reports the company has a price-to-book ratio of 0.8179.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | N/A | -100% |
2023-12-31 | 0.9449 | -38.98% |
2022-12-31 | 1.55 | -33.56% |
2021-12-31 | 2.33 | 13.96% |
2020-12-31 | 2.05 | 28.07% |
2019-12-31 | 1.60 | -7.9% |
2018-12-31 | 1.73 | -59.57% |
2017-12-31 | 4.29 | 18.13% |
2016-12-31 | 3.63 | -17.32% |
2015-12-31 | 4.39 | -20.2% |
2014-12-31 | 5.50 | 50.81% |
2013-12-31 | 3.65 | 57.25% |
2012-12-31 | 2.32 | 123.09% |
2011-12-31 | 1.04 | -49.98% |
2010-12-31 | 2.08 | 18.19% |
2009-12-31 | 1.76 | 26.16% |
2008-12-31 | 1.39 | -59.19% |
2007-12-31 | 3.42 | -29.7% |
2006-12-31 | 4.86 | 28.19% |
2005-12-31 | 3.79 | -33.19% |
2004-12-31 | 5.67 | 13.45% |
2003-12-31 | 5.00 | 36.11% |
2002-12-31 | 3.67 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Quest Diagnostics
DGX | 2.18 | 166.39% | ๐บ๐ธ USA |
LabCorp LH | 2.13 | 160.00% | ๐บ๐ธ USA |
RadNet RDNT | 4.31 | 427.53% | ๐บ๐ธ USA |
Psychemedics PMD | 2.00 | 144.61% | ๐บ๐ธ USA |
NeoGenomics
NEO | 1.87 | 128.29% | ๐บ๐ธ USA |
Qiagen QGEN | 2.29 | 180.55% | ๐ณ๐ฑ Netherlands |